The Impact of Multi-Touch Functional Digital Game on Intelligence and Vitality for the Community-dwelling Elderly
NCT04873843, Not applicable, Completed, Samsung Medical Center
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Impact of Multi-Touch Functional Digital Game on Intelligence and Vitality for the Community-dwelling Elderly | ClinicalTrials.gov |
| NCT number | NCT04873843 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 32 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Samsung Medical Center | ClinicalTrials.gov |
| Conditions | Aging | ClinicalTrials.gov |
| Interventions | Functional digital game training group, Individual cognitive training | ClinicalTrials.gov |
| First posted | 2021-05-05 | ClinicalTrials.gov |
| Last updated | 2022-09-22 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from baseline performance on Stroop test (Neuropsychological test) after the intervention (Day 13). | Baseline, After the intervention (Day 13) | It measures a participant's processing speed, selective attention and inhibitory control. The participant will be asked to read 'word' of the colored words or 'name of the color' of the colored words in separate trials. The main scores produced in this test are completion time and errors. The contrast score of the two trial's completion time means interference. | ClinicalTrials.gov |
| Secondary | Change from baseline performance on Fluency Test (Neuropsychological test) after the intervention (Day 13). | Baseline, After the intervention (Day 13) | This is a generative naming test. That measure how many words you can spontaneously speak within a limited time of words that fall into a specific category (e.g. animals, store goods, vegetables) or words starting with a letter (e.g. F • A • S or C·F·L). | ClinicalTrials.gov |
| Secondary | Change from baseline performance on Trail Making Test (Neuropsychological test) after the intervention (Day 13). | Baseline, After the intervention (Day 13) | It consists of type A and type B trials. The participant should connect the numbers (1\~25) as quickly as possible in Type A trial, and connect the numbers (1\~13) and alphabets (A\~L) alternatively as quickly as possible in type B trial. The main scores produced in this test are completion time and errors. Higher score means worse performance. | ClinicalTrials.gov |
| Secondary | Change from baseline performance on Digit Span Test (Neuropsychological test) after the intervention (Day 13). | Baseline, After the intervention (Day 13) | It measures auditory attention span and includes forward and backward trials. The participant listens to a series of numbers and calls the sequence correctly. The sequence increases in each trial. The final score is the longest number of sequential digits that the participant can remember correctly. The scores range from 3 to 8. The higher the score, the better the performance. | ClinicalTrials.gov |
| Secondary | Change from baseline performance on Auditory Verbal Learning test (Neuropsychological test) after the intervention (Day 13). | Baseline, After the intervention (Day 13) | It measures participant's verbal memory. The participant will hear 15 words and recall them immediately and after 20 minutes again. The main scores produced in this test are the numbers of recalled words of the immediate and delayed trials. Immediate memory score is the sum of 5 trial's correct response and score ranges between 0 and 60. Delayed memory score is the correct response of the delayed trial and the score range is 0 to 15. Higher score means better performance. | ClinicalTrials.gov |
| Secondary | Change from baseline activity on functional Near-Infrared Spectroscopy (fNIRS) during the intervention(Day 1 and 12)and after intervention completion(Day 12) | Baseline, during the intervention(Day 1 and 12), Through intervention completion(Day 12) | It measures brain activity during cognitive tasks to see if cognitive training affects brain function. | ClinicalTrials.gov |
| Secondary | Change from baseline activity on Contrasting Program/Go-No-Go test after the intervention (Day 13). | Baseline, Day 13(After the intervention) | The Contrasting Program and go-no go test requires a subject to emit a simple motor response to one cue while inhibiting the response in the presence of another cue. This test has been effective in demonstrating impulsivity (elevated commission error rate) in elderly with attention deficit. | ClinicalTrials.gov |
| Secondary | Change from baseline activity on Geriatric Depression Scale (GDS) after the intervention (Day 13). | Baseline, After the intervention (Day 13) | GDS is a 15-item self-report assessment used to identify depression in the elderly. A score of 0 to 5 is normal. A score greater than 5 suggests depression | ClinicalTrials.gov |
| Secondary | Change from baseline activity on health-related quality of life instrument with 20 items (HINT-20) after the intervention (Day 13). | Baseline, After the intervention (Day 13) | The total score of the HINT-20 is converted to a 0-100 scale, with higher scores indicating better health-related quality of life. | ClinicalTrials.gov |
| Secondary | Change from baseline activity on General Self-Efficacy Scale (GSE) after the intervention (Day 13). | Baseline, After the intervention (Day 13) | General self-efficacy (GSE), individuals'belief in their ability to perform well in a variety of situations. General self-efficacy (GSE) is the belief in one's competence to attempt difficult or novel tasks, and to cope with adversity arising from specific demanding situations. | ClinicalTrials.gov |
| Secondary | Change from baseline activity on International Physical Activity Questionnaire after the intervention (Day 13). | Baseline, After the intervention (Day 13) | Physical Activity Questionnaire collects information on physical activity participation in three settings (or domains) as well as sedentary behaviour, comprising 16 questions. | ClinicalTrials.gov |
| Secondary | User Satisfaction Questionnaire after intervention. | After the intervention (Day 13) | We evaluate the satisfaction questionnaire for each training. | ClinicalTrials.gov |
| Secondary | Change from baseline activity on smart band activity through intervention completion(Day 12). | Baseline, through intervention completion(Day 12) | Each participant was given an smart band(number of steps count) and instructed to wear it on the wrist during waking hours until completion of the training program. This included both intervening training days (totaling 10). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Go/No-Go Task | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)